Tecnifar was born within the Luso-Fármaco group, founded in 1945 by two families, always maintaining a family business nature.

Tecnifar took its first steps in 1969, together with the Instituto Luso-pharmaco and Medicamenta.

Tecnifar acquires its autonomy, maintaining to this day 100% national capital, managed by the Chaves Costa Family.

Tecnifar was the first Portuguese company to receive a license from a multinational (MSD) with DINUL (famotidine) and Tensazol (enalapril).

In August 1995, Tecnifar received the AIM – Market Introduction Authorization for Diplexil-R (Semisodium Valproate), which is still the company's first product.

In April 2009, Tecnifar, in partnership with TECNOPHAGE, registered the first patent in its name in the USA, Japan and Russia, for the discovery of a new specific bacteriophage.

The Chaves Costa Family, founder and management of Tecnifar for three generations, acquires the entire share capital, becoming the sole shareholder of Tecnifar. With António Chaves Costa as President of the Board of Directors since 2010.

The Tecnifar CH – Consumer Health line is created, today being a reference in the sale of Non-Prescription Medicines (MNSRM), Medical Devices and Food Supplements.

The registration of Diplexil-R in the United Kingdom, the main product in our portfolio, was completed, being Tecnifar's 1st out-licensing.

Tecnifar was distinguished by IAPMEI as a leading SME in 2021, 2022, 2023 and 2024, for the quality of its Performance and Risk Profile.